A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Felbamate (Felbatol)

Felbamate prevents seizures by stabilizing electrical activity in the brain.

First FDA approval1993-07-29
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$20.0M in CY2024 Part D spend38K claims · 6K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.368/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.50
Across all dosage forms in distribution.
Highest NADAC
$16.88
Wide spread — brand-strength NDCs still in market.
Plans with PA
22 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Felbamate used for?

Felbamate prevents seizures by stabilizing electrical activity in the brain.

Is there a generic for Felbamate?

Yes. 11 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Felbamate?

Across 329 Part D plans, Felbamate averages $2.50/unit (NADAC). Lowest available: $0.368/unit. Highest in distribution: $16.88/unit.

Is Felbamate on the FDA shortage list?

No. Felbamate is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Anti-epileptic Agent6 alternatives in D1
01
Ethosuximide
Brand: Zarontin
$0.092Lowest NADAC
8Generic mfrs
$2.3MCY24 Part D spend
Compare →
02
Lamotirigine
Brand: Lamotrigine
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Lamotrigine
Brand: LAMICTAL
$0.029Lowest NADAC
22Generic mfrs
$327.2MCY24 Part D spend
Compare →
04
Lamotrigine Chewable Dispersible
Brand: lamotrigine
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Lamotrigine Er
Anti-epileptic Agent
$0.371Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
06
Lamotrigine Extended Release
Anti-epileptic Agent
$0.371Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.